CBIO
Financials
- Market Capitalization 419.09 M
- Employee 44
- Founded 2024
- CEO N/A
- Website www.crescentbiopharma.com
- Headquarter Cayman Islands
- FIGI N/A
- Industry Drug Manufacturers—General
Related tickers
| # | Name | Price | 24h % | 7d % | 1M % | 1Y % | Market Cap | Last 7 Days | |
|---|---|---|---|---|---|---|---|---|---|
| 2127 |  MAZE Maze Therapeutics, Inc. - Common Stock | 29.88 USD | +2.40% | -9.01% | +22.81% | -33.64% | 1.65 B USD | ||
| 2854 |  EIKN Eikon Therapeutics, Inc. - Common Stock | 10.19 USD | -2.39% | -12.16% | +7.04% | -40.23% | 551.67 M USD | ||
| 3106 |  UPB Upstream Bio, Inc. - Common Stock | 7.16 USD | -1.65% | -8.91% | +15.67% | -39.32% | 389.65 M USD | ||
| 3236 |  QTTB Q32 Bio Inc. - Common Stock | 18.46 USD | -13.66% | +35.54% | +44.44% | +809.36% | 313.02 M USD |
Frequently asked questions about Crescent Biopharma, Inc. - Common Stock
What is the Crescent Biopharma, Inc. - Common Stock stock price today?
The current price of Crescent Biopharma, Inc. - Common Stock (CBIO) is 15.2. Over the past 24 hours, the stock has changed by -3.12%. Follow the CBIO chart for real-time price dynamics.
What is the stock ticker of Crescent Biopharma, Inc. - Common Stock?
Crescent Biopharma, Inc. - Common Stock trades under the ticker CBIO. Tickers can differ by exchange, so always check the exchange and instrument details before trading.
Is Crescent Biopharma, Inc. - Common Stock stock going up?
CBIO has changed by -10.75% over the last week, -14.75% over the last month, and +18.75% over the last year. Review the chart to see whether the current move is part of a broader trend.
What was Crescent Biopharma, Inc. - Common Stock net income for the last quarter?
Crescent Biopharma, Inc. - Common Stock reported net income of -23.28 M for the last quarter. The previous quarter showed -92.4 M, which means net income changed by +74.80%.
How many employees does Crescent Biopharma, Inc. - Common Stock have?
As of the latest available data, Crescent Biopharma, Inc. - Common Stock has 44 employees. Workforce size can provide additional context about the company's scale and operations.
What is Crescent Biopharma, Inc. - Common Stock EBITDA?
Crescent Biopharma, Inc. - Common Stock EBITDA is -24.66 M, and its EBITDA margin is -2 373.92%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.
How can I buy Crescent Biopharma, Inc. - Common Stock stock?
You can buy Crescent Biopharma, Inc. - Common Stock (CBIO) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.
Should I invest in Crescent Biopharma, Inc. - Common Stock stock?
Investing in Crescent Biopharma, Inc. - Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CBIO chart and related analysis on metatrader.com as part of your research.